January 2024, Vol 14, No 1

On December 1, 2023, the FDA accelerated the approval of pirtobrutinib (Jaypirca; Eli Lilly) for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received ≥2 lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. Read More ›

For this Interview with the Innovators series, several interviews were conducted with executives and scientists from Genmab, an international biotech company with 24 years of experience in developing cutting- edge antibodies and antibody technology. Read More ›